HankMed Announces Acquisition of BD's Villamarzana Facility in Italy, Securing $18.43 Million in Confirmed 2025 Revenue

Recently,Hantech Announces Completion of Full Acquisition of BD's (Becton, Dickinson and Company) Factory in Villamarzana, Italy (Including Core Assets Such as Land, Plant Facilities, and All Production Equipment)At the same time, Hantech Medical and BD reached an important manufacturing service agreement. According to the terms of the agreement, BD will continue to purchase the required products and services from the Villamarzana factory taken over by Hantech Medical, aiming to ensure the continuity and long-term stability of the business cooperation between both parties.

This acquisition and the signing of the cooperation agreement further deepen the partnership between Hantech and BD. Looking back, Hantech was awarded the only "Partner Award" by BD in 2018 for its outstanding product quality and efficient service standards. Subsequently, in 2021 and 2022, Hantech once again excelled, successively winning BD's "New Product Achievement Award" and Dentsply Sirona’s "Outstanding Supplier Partner Award."

The new factory will contribute at least $18.43 million!

The Villamarzana factory, acquired this time, is located in northern Italy, with 125 existing employees and a history that can be traced back to 1973. Covering an area of 49,389 square meters (approximately 74.15 mu), this modern factory is equipped with comprehensive production facilities, including a highly efficient 100,000-level cleanroom, a laboratory with strong scientific research capabilities, a precision mold workshop, an advanced R&D testing workshop, and a well-organized warehouse, all of which together form a solid foundation for the factory's efficient production and excellent product quality.

Notably, the Villamarzana plant has excelled in key performance indicators such as safety, compliance, quality, delivery, cost control, and team ESG (Environmental, Social, and Governance) management, ranking among the top in the industry. In terms of the market, the Villamarzana plant has also performed exceptionally well, securing orders worth up to $18.43 million for the year 2025.

It is precisely based on its outstanding performance that Hantech Medical has incorporated it into the company's portfolio. Zhang Jianming, General Manager of Hantech Medical, publicly stated: "We will leverage our innovative leadership and technological advantages to integrate the manufacturing and service capabilities of the acquired factory, providing R&D and manufacturing services to global customers from both China and Italy, and accelerating our global layout."
Currently, the Hantech medical team is actively streamlining and planning to enhance the production efficiency of the acquired factory. Based on the demands of upcoming additional orders, an expansion plan is being formulated. By the second quarter of next year, a significant 45% increase in production capacity is expected at Hantech's Italian factory, enabling better service for customers in Europe and North America. In the future, the Hantech Italian factory is projected to generate at least $18.43 million in revenue next year, providing strong momentum for Hantech's global strategy.

Hantech Consolidates CDMO Leadership Position

Hantech focuses on the R&D and manufacturing (CDMO) of medical consumables in niche markets, as well as the independent innovation of core components. Its products include minimally invasive interventional catheters and related consumables, infusion and drug delivery consumables, dental consumables, diabetes treatment consumables, and epidemic prevention products.

As of now, Hantech has a total of 102 R&D technical personnel, established close industry-university-research-medical cooperation systems with multiple scientific research institutes, universities, and hospitals, and set up a postdoctoral workstation in Zhejiang Province. With strong scientific research capabilities, it currently owns 138 patents and 58 trademark rights.

At the CDMO business level, Hantech provides full lifecycle CDMO services, offering customized services for silicone and rubber components to the medical device industry. The service scope covers the entire process, including injection molding, extrusion, vulcanization, liquid silicone molding, assembly, printing, packaging, and sterilization. With a diverse range of products, it can meet various customer needs.

To establish a faster response speed, Hantech Medical has set up a rapid prototyping center in Shanghai. The center is able to quickly deliver samples to customers and continuously provide product design optimization services, ensuring that customers can obtain satisfactory product solutions at the first time.

In terms of product innovation, Hantech's independently developed disposable insulin pen needles and disposable sterile insulin syringes have both obtained U.S. FDA 510(k) registration, and the disposable insulin pen needles have received China's Class III medical device registration certificate.

In terms of capacity expansion, Hantech has also been making frequent moves. In January this year, the company successfully topped out its new factory building, which covers an area of 194.8 mu (129,859 square meters) with a total construction area of 162,143 square meters. Coupled with the acquisition of the Villamarzana factory in Italy, Hantech's global service capabilities will be significantly enhanced, enabling it to better provide high-quality products and services to customers worldwide and accelerate the implementation of its globalization strategy.

Diversified "Going Overseas" Paths for Chinese-Made Medical Devices

With the rapid advancement of technology in China's medical device industry, the competitiveness of domestically produced medical devices on the international stage is growing stronger, and expanding overseas has become an unstoppable new trend in the industry. According to data from the General Administration of Customs of China, during the period from January to November 2022, the total export value of China’s medical devices reached 444.179 billion yuan, with the full-year export value expected to exceed 478.5 billion yuan.

From the perspective of corporate dynamics, this wave of overseas expansion is sweeping through the entire industry with unprecedented momentum. In the past year, several listed companies in the medical device sector, such as Mindray Medical, Well Lead Medical, and Blue Sail Medical, have actively expanded their overseas presence through various means, including mergers and acquisitions, investment in factory construction, and the establishment of multinational joint ventures.

Among these overseas expansion strategies, mergers and acquisitions (M&A) are undoubtedly an effective means to quickly enter the target market. Through M&A, companies can rapidly acquire advanced technologies, well-known brands, and significant market share. In contrast, investing in factory construction allows for better control over product quality and supply speed, ensuring stable product availability on a global scale. Establishing cross-border joint ventures is a win-win strategy that involves sharing resources and technology with local partners to collaboratively develop the market, though this process often requires a longer period of adjustment.

China's Leading Medical Device Manufacturer, Mindray, Continues to Accelerate Its Global Expansion Through Acquisitions. In November 2023, Mindray successfully completed the cash acquisition of 75% equity in DiaSys, making DiaSys its officially controlled subsidiary. Through this acquisition, Mindray will gradually integrate and enhance the supply chain platform for overseas in-vitro diagnostic businesses such as hematology, biochemistry, and chemiluminescence, further strengthening its local production, warehousing, logistics, and service capabilities in international markets.

Blue Sail Medical, on the other hand, has chosen to establish a transnational joint venture to expand overseas. Its wholly-owned subsidiary, Shandong Health Technology, plans to introduce Thai industrial investor HKG through a capital increase and share expansion. Both parties will combine their respective advantageous resources to invest in global expansion, new product development, and new business initiatives, jointly building Shandong Health Technology into a high-quality transnational joint venture.

Weili Medical, on the other hand, has adopted the approach of investing in factory construction to expand into overseas markets. In May 2024, Weili Medical injected an additional $9.5 million of its own funds into its wholly-owned subsidiary, Weili Global Co., Ltd., which served as the main investor. Together with the company's chairman, Bin Xiang, they invested a total of $10 million to establish a subsidiary in Mexico and develop a production base. This move has laid a solid foundation for the company’s further expansion in the global market.

Looking ahead, as Chinese medical device companies continue to accelerate their overseas expansion, we have every reason to believe that domestically produced medical devices will shine even brighter in the global market.